Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
772.700.06%
QQQ
717.030.09%
BTC/USD
80826.770.5528%
DIA
536.820.02%
GLD
410.870.16%
TLT
82.140.09%

Fate Therapeutics Inc

FATENASDAQ
Trade with Public
Trade with Public
$2.42
-0.03-1.22%
At close: Sep 3, 5:00 PM EST
$2.49
0.06582.72%
After Hours: 7:26 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Fate Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Fate Therapeutics (FATE).

Price Target Range — 11 Quarters

Analyst Consensus — 12 Analysts

6Buy
5Hold
1Sell
Consensus RatingBuy# Analysts12Avg. Consensus PT$6Upside to Avg. PT+134.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026Piper SandlerEdward TenthoffPT RaiseOverweight$6→$8
Aug 14, 2026Wells FargoYanan ZhuPT RaiseEqual-Weight$3→$4
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and raises the price target from $2.5 to $3.5.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Buy and maintains $7 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $5 to $7.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Buy and maintains the price target from $5 to $5.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved